Krka, d. d. (KRK.WA) Stock Analysis & Winston Score

Krka is a Slovenian pharmaceutical company that makes generic medicines — drugs that copy brand-name medications once their patents expire. It sells thousands of products across categories like heart disease, diabetes, and mental health, primarily to hospitals, pharmacies, and healthcare systems across Europe and beyond. Krka is one of the largest generic drug manufacturers in Central and Eastern Europe. The company earns money by selling finished medicines, over-the-counter health products, and veterinary drugs across more than 70 countries, with its strongest markets in Russia, Eastern Europe, and Western Europe. Its competitive edge comes from a vertically integrated manufacturing model — it produces many of its own active ingredients, which helps control costs and quality. The key risk Krka faces is its significant exposure to Russia and Eastern European markets, where currency swings, sanctions-related disruptions, and geopolitical instability can meaningfully impact revenue and profitability.